Yazar "Baramidze, A." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3(Elsevier, 2023) Makharadze, T.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3(Elsevier Science Inc, 2023) Kalinka, E.; Bondarenko, I.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Makharadze, T.[Abstract Not Available]Öğe Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]
